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Abstract
We have generated a novel monoclonal antibody targeting human FGFR1c (R1c
mAb) that caused profound body weight and body fat loss in diet-induced obese
mice due to decreased food intake (with energy expenditure unaltered), in turn
improving glucose control. R1c mAb also caused weight loss in leptin-deficient ob/
ob mice, leptin receptor-mutant db/db mice, and in mice lacking either the
melanocortin 4 receptor or the melanin-concentrating hormone receptor 1. In
addition, R1c mAb did not change hypothalamic mRNA expression levels of Agrp,
Cart, Pomc, Npy, Crh, Mch, or Orexin, suggesting that R1c mAb could cause food
intake inhibition and body weight loss via other mechanisms in the brain.
Interestingly, peripherally administered R1c mAb accumulated in the median
eminence, adjacent arcuate nucleus and in the circumventricular organs where it
activated the early response gene c-Fos. As a plausible mechanism and coinciding
with the initiation of food intake suppression, R1c mAb induced hypothalamic
expression levels of the cytokines Monocyte chemoattractant protein 1 and 3 and
ERK1/2 and p70 S6 kinase 1 activation.
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Introduction
According to the World Health Organization (WHO), obesity has more than
doubled since 1980 and in 2008 at least 1.5 billion adults were overweight and 500
million were obese worldwide, resulting in an increased incidence of type 2
diabetes, cardiovascular disease and premature deaths (www.who.int). Recently,
the Fibroblast Growth Factor Receptor 1 (FGFR1) SNP rs7012413*T was found to
be associated with obesity in four different cohorts [1]. In addition, adipose tissue
FGFR1 mRNA and protein levels were elevated in obese subjects and Fgfr1 mRNA
levels were increased in the hypothalamus of diet-induced obese (DIO) rats [1],
showing that FGFR1 is a novel human obesity candidate gene that may affect
metabolism and control of food intake.
The mammalian Fibroblast Growth Factor (FGF) family consists of 22
members and there are 4 FGFRs identified existing in different splice variants with
different ligand-binding specificity, reviewed in [2,3]. Antagonizing FGFR1c with
the monoclonal antibody (mAb) IMC-A1 caused weight loss due to reversible
hypophagia in animals [4]. Paradoxically, an FGFR1-activating mAb has also been
found to cause body weight loss in mice via a combination of both decreased food
intake and increased energy expenditure [5].
Here, we describe the identification of a novel fully human FGFR1c targeting
mAb (R1c mAb) possessing both antagonistic and agonistic properties that caused
in DIO mice profound body weight and body fat loss via reversible hypophagia
leading to improved glucose control. Importantly, R1c mAb accumulated and
increased neuronal activity in the median eminence, adjacent arcuate nucleus and
in other circumventricular organs. As the basis for a plausible mechanism, R1c
mAb induced a specific subset of chemokines and activated ERK1/2 and p70 S6




All animal experiments were approved by the Gothenburg Ethics Committee for
Experimental Animals.
Phage display identification of an anti-FGFR1c monoclonal
antibody
Phage display selections were performed according to the methods described in
Dobson et al using naïve human antibody libraries [6]. Multiple rounds of phage
display selection were performed using biotinylated human FGFR1c-extracellular
domain (ECD) produced by MedImmune, with deselection using unlabelled
human FGFR1b Fc-fusion protein (R&D Systems, Minneapolis, MN). To identify
antibodies capable of specific FGFR1c antagonism, crude bacterial peri-plasmic
extracts containing scFv antibodies from the selection outputs were prepared [6]
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and analyzed in an assay designed to measure the binding of FGF2 (produced by
MedImmune) to FGFR1c. Full length human FGF2 (UniProt: P09038), fused to a
C-terminal hexa-histidine tag, was expressed in E. coli Rossetta (DE3) pLysS
(Merck KGaA, Darmstadt, Germany). Expressed protein was purified by
immobilised nickel chromatography followed by size exclusion chromatography.
The binding of flag-tagged FGF2 to cryptate labelled FGFR1c-ECD-Fc (R&D
Systems) was detected using an XL665 labelled anti-Flag antibody (Cisbio, France)
and inhibitors of this interaction were identified. A similar assay to measure
inhibition of FGF2 binding to FGFR2c was used as negative screen. FGFR1c
specific ScFv were converted to IgG. FGFR1c specific IgG was further profiled in
FGF2 induced proliferation using BaF3huFGFR1c cells and a FGF2 induced Ca2+
release assay in NIH3T3huFGFR1c cells. The most potent in vitro antagonists were
selected to test in vivo. Fragment antigen-binding (FAb) fragments were generated
by papain (Sigma) digestion of R1c mAb IgG followed by MabSelect SuRe (GE
Healthcare) purification.
Receptor binding and specificity assay
Monomeric human FGFR1c (FGFR1bIIIc), FGFR2c (FGFR2bIIIc), FGFR3c, and
FGFR4 were produced by MedImmune. The extracellular domains of human
FGFRs were fused to a C-terminal FLAG epitope tag and a deca-histidine tag and
were expressed in human embryonic kidney (HEK) cells using an episomal
transient expression system. Purification was achieved by ultra-filtration followed
by immobilised nickel chromatography and size exclusion chromatography.
The Octet RED system (ForteBio, UK) was used for real-time, label-free analysis
of R1c mAb interaction with FGFR1c. All Octet experiments were run at RT and
reagents were prepared in 0.1% BSA, 0.02% Tween20 PBS, pH 7.4 kinetic buffer.
Streptavidin sensors were pre-soaked off-line in 200 ml of kinetic buffer and
loaded with biotinylated Protein G (Thermo Scientific, UK) prior to loading with
10 mg/ml of R1c mAb or a control mAb. The receptor association phase was
measured by incubating the sensor in a titration curve of FGFR1c ECD or kinetic
buffer blank for 10 min. The receptor dissociation phase was subsequently
measured by incubating all the sensors in kinetic buffer for 10 min. After data
processing to subtract reference trace, data analysis was performed using the Data
Analysis software package provided with the Octet RED system. Binding to the
other FGFRs was assessed by ELISA. Nunc maxisorp plates were coated with
0.5 mg/ml of FGFR overnight, blocked with 3% Marvel-PBS buffer and then
washed with PBS. Anti-FGFR or control antibodies, ranging from 0.4 to 100 nM,
were added and following incubation plates were washed and detection anti-
human Fc-HRP added. The HRP substrate TMB (3, 3’, 5, 5’-tetramethylbenzi-
dine) was added and the reaction stopped and read at OD 450 nm using an
Envision plate reader.
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FLIPR ligand induced Ca
2+
Release Assays
To study antibody effects on Ca2+ release stimulated by FGFs 1, 2, 4, 5, and 6,
NIH3T3 cells overexpressing human FGFR1c were seeded at a density of 7,000
cells per well in 25 ml of DMEM, 10% FBS, 2 mg/ml puromycin and incubated
overnight at 37 C̊/5% CO2. Media was then removed and 25 ml of Fluo-4 NW,
reconstituted as described by the manufacturer (Invitrogen, Carlsbad, CA)
including 2.5 nM probenicid, was added to each well and plates were incubated
for 30 min at 37 C̊/5% CO2. All reagents were prepared in 20 mM HEPES, 0.1%
BSA, HBSS assay buffer. After equilibrating the cells to RT for 10 min, R1c mAb
or control mAb was added to the plates and incubated for 15 min at RT. Final
assay concentrations were 0.5 nM FGF1, 0.5 nM FGF2, 4 nM FGF4, 40 nM FGF5,
or 4 nM FGF6. For FGF4 and FGF6 assays, heparin was added in the pre-
incubation step. FGF1, FGF2 and FGF5 assays did not require heparin. FGF
agonist was then added to the plates and Ca2+ transients were recorded
immediately on a FLIPR Tetra (Molecular Devices, UK). Fluorescence was excited
at 470_495 nm and emission was measured at 515_575 nm. Data was analyzed by
taking maximum peak height minus background and calculating % of maximum
response.
Transfection of BaF3 Cells and Proliferation Assays
BaF3 cells (murine interleukin-3 dependent pro-B cell line) overexpressing human
FGFR1c were kindly provided by Prof. David Ornitz (Washington University
School of Medicine, St Louis, Missouri, USA). BaF3huFGFR1c cells were
maintained in RPMI 1640 (Invitrogen) medium supplemented with 8.8%
Newborn bovine serum, 0.04% mouse IL3, 0.09% 2ME, 1.8% Glutamax-I and 1%
G418. BaF3huFGFR1c cells were transfected with a-Klotho or b-Klotho in pEF-
DEST51 expression vector (Invitrogen) by nucleofection using the Amaxa
Nucleofector Kit V (Lonza). Transfectants expressing a-Klotho or b-Klotho were
selected and maintained by incubation in the presence of 4 mg/ml blasticidin.
Proliferation of cells in the presence of FGF ligands was measured using a
Luminescent Cell Viability Assay (Promega, USA). Briefly, the transfectants were
washed to remove IL3 and plated to a density of 8,000 cells per well in 384-well
plates. BaF3huFGFR1c cells were used for the FGF2 assay, BaF3huFGFR1c/b-
klotho cells were used for the FGF19 and FGF21 assays, and BaF3huFGFR1c/a-
klotho cells were used for the FGF23 assay. The proliferation assay media was
RPMI 1640 (Invitrogen, Carlsbad, CA) medium supplemented with 8.8%
Newborn bovine serum, 0.09% 2ME, 1.8% Glutamax-I, 1% G418 and 10 ug/ml
heparin. The final FGF concentrations were 0.02 nM FGF2, 50 nM FGF19, 50 nM
FGF21, or 0.02 nM FGF23. The cells were stimulated with FGFs with or without
R1c mAb or control mAb and incubated at 37 C̊ for 72 h. Prior to addition of
CellTiterGlo reagent (Promega, USA), the cells were equilibrated to room
temperature for 30 min. Luminescence was read on an Envision Multilabel reader
(Perkin Elmer, UK).
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Animals, diets, food intake analysis and body composition
DIO C57BL/6J mice (Harlan, the Netherlands) had free access to a high-fat diet
(HFD) containing (energy percentage) 60% fat, 20% carbohydrates, and 20%
protein, with a total energy content of 5.2 Kcal/g (D12492; Research Diets, New
Brunswick, NJ) for 6–12 weeks before treatment starts. A pair-feeding experiment
was performed over four days in which one group of DIO mice dosed with a
single injection of R1c mAb were fed ad libitum and two groups of DIO mice
receiving a single injection of control mAb were fed either ad libitum or pair-fed
twice daily to match the food intake of R1c mAb treated DIO mice fed ad libitum.
Leptin-deficient ob/ob mice, leptin receptor-mutant db/db mice (Harlan), and
melanocortin receptor 4 (Mc4r)-deficient mice [7] were kept on regular chow diet
containing (energy percentage) 12% fat, 62% carbohydrates, and 26% protein,
with a total energy content of 3 Kcal/g (R3; Lactamin, Kimstad, Sweden) and
melanin-concentrating hormone receptor (Mchr)-deficient mice [8] were kept on
HFD (D12492; Research Diets). Cumulative food intake was analyzed in single
housed mice in an automated food intake analysis system (AstraZeneca, Mölndal,
Sweden). The mice were adapted to the system for at least 5 d before treatment
start and statistical analyses were performed on bi-hourly food intake during the
first 12 h post treatment start.
Body composition analysis was performed on isoflurane (Forene, Abbot
Scandinavia AB, Sweden) anesthetized mice with dual-energy X-ray absorptio-
metry (DEXA, PIXImus Lunar, GE Medical Systems, Madison, WI). At
termination (9–11 a.m.), plasma was isolated from isoflurane anesthetized mice
and organs were collected, weighed and snap frozen in liquid N2 and stored at
280 C̊.
Plasma biochemistry
Plasma total adiponectin levels were measured using a radioimmunoassay from
Linco Research (St. Charles, MO) and plasma leptin with an ELISA from Chrystal
Chem. Inc. (Downers Grove, IL). Plasma cholesterol levels were measured with a
kit from Roche Diagnostics (Mannheim, Germany), alanine aminotransferase
(ALT) with a kit from ABX Diagnostics (Montpellier, France), b-hydroxybutyrate
with a kit from Randox Laboratories (Antrim, UK) and non-esterified fatty acids
(NEFAs) with a kit from WAKO Chemicals (Neuss, Germany).
Oral glucose tolerance test
Oral Glucose Tolerance Tests (OGTTs) were performed 1 p.m. after a 4 h fast by
oral administration of 2 g glucose per kg body weight. Blood (12 ml) was sampled
from the tail vein at 0, 15, 30, 60 and 120 min for determination of glucose (2 ml,
Accu-Chek, Roche Diagnostics, Mannheim, Germany) and insulin (265 ml,
Ultra-sensitive mouse insulin ELISA kit, Crystal Chem. Inc., Downers Grove, IL)
levels.
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Indirect calorimetry and spontaneous locomotor activity
Oxygen consumption (vO2) and carbon dioxide production (vCO2) were
measured using a CLAMS open circuit calorimetry system (Oxymax, Columbus
Instruments, Columbus, OH). Energy expenditure (Kcal/h) was calculated:
(3.815+1.232RER)6vO2, where RER is the respiratory exchange ratio [volume of
CO2 produced per volume of O2 consumed (both ml/kg/min)] and vO2 is the
volume of O2 consumed per h per kg mass of the animal. The value of energy
expenditure was correlated to individual body weights. Horizontal spontaneous
locomotor activity was measured continuously in the CLAMS system.
Assessment of general behavior
An elevated zero maze system (Accuscan Instruments Inc., Columbus, OH) was
used to assess anxiety related behavior as previously described [9]. Mice were
acclimatized once to the system 3–4 h after dosing and analyzed 24 h later.
Memory and learning ability was assessed by a passive avoidance approach in the
Shuttle box system (Accuscan Instruments Inc., Columbus, OH) as described [9].
Assessments were performed 50 h after dosing and then repeated 75 h after
dosing. To assess signs of depression, a forced swim test approach was used in
water filled plexiglas cylinder (AstraZeneca R&D, Mölndal, Sweden). Active swim
time was assessed during the last 4 minutes of the test as previously described [9].
Assessment of depression was performed 50 h post dosing.
Pancreas a- and b-cell mass
Sample preparation and immunohistochemistry were performed according to Sun
et al [10]. Isolated pancreas were fixed in 10% buffered formalin and embedded in
paraffin wax within 24 h of removal. Head-to-tail sections (4 mm lengthwise)
were cut and incubated overnight at 37 C̊ on superfrost slides. Slides were
submerged sequentially in xylene followed by decreasing concentrations of
industrial methylated spirits for removal of paraffin wax. Slides were blocked in
5% (vol./vol.) goat serum in Tris buffered saline with 0.05% (vol./vol.) Tween
(TBST) for 20 min at room temperature then incubated sequentially with primary
(1:200 mouse anti-glucagon ab10988, Abcam, Cambridge, UK) and secondary
glucagon antibodies (1:200 rabbit anti-mouse IgG antibody:TRITC conjugate; T-
2402, Sigma), for 60 minutes followed by a further block in 5% goat serum in
TBST prior to sequential incubation in primary (1:50 Guinea pig anti-insulin,
Dako A0564) and secondary insulin antibodies (1:400 goat anti guinea pig
AlexaFluor 488, A11073, Invitrogen). Hoeschst (2 mM) was included in the final
incubation as a fluorescent nuclear stain and sections were mounted using
FluorSave mounting Reagent (Merck 345789). Six longitudinal sections, at 40
micron intervals were imaged per pancreas, with the SpGreen and SpOrange
filters respectively on a Zeiss Axio Imager M1 (Carl Zeiss, Jena, Germany)
operated through the Metafer software (MetaSystems, Waltham, MA, USA). A
custom designed Metafer software classifier enabled mapping of all pancreatic
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tissue. Definiens image analysis software (Munich, Germany) quantified all
fluorescent images. The results are expressed as a percentage of total pancreatic
area.
RNA preparation and quantitative real-time PCR
Total RNA was extracted using Qiazol and disruption of the sample in a Mixer
Mill 300 (Qiagen, Valencia, CA). RNA clean-up and DNase digestion were
performed using RNeasy Mini Kit (Qiagen). RNA content and quality was
assessed using Nanodrop (ThermoScientific, Wilmington, DE). First strand cDNA
was synthesized using the High Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, CA). Real-time PCR analysis was performed with an ABI Prism 7900
Sequence Detection System (Applied Biosystems) using 59-FAM and 39-TAMRA
labeled fluorogenic oligonucleotide probes or primers designed for use for SYBR-
Green detection. Primers/probes were purchased from Sigma-Genosys (Haverhill,
UK). The relative expression levels were calculated by using the standard curve
method in order to define an arbitrary expression level. This data was then
normalized against mouse acidic ribosomal phosphoprotein P0 (m36B4)
expression for each sample. Sequences for primers and probes are presented in
Table 1.
Tissue and cell protein extraction and Western blot
Hypothalamus or white adipose tissue protein extracts were generated by
homogenization in ice cold T-PER protein extraction reagent (Pierce, Rockford,
IL) containing a protease inhibitor cocktail (Complete Mini and phosphoSTOP,
Roche Diagnostics), with a single-use pestle in a 1.5 ml Eppendorf Tube (VWR,
Radnor, PA). Homogenates were centrifuged (4 C̊, 20,0006g for 15 min) and the
protein content of the lysate quantitated using BCA Assay Reagent (Pierce).
Mouse embryonic hypothalamic N46 cells were from Cellutions Biosystems
(Burlington, Canada) and cultured in Dubecco’s Modified Eagle Medium
(DMEM) (Sigma) supplemented with 10% FBS (Hyclone, Erembodegem,
Belgium). Confluent cells were serum starved in medium containing 5 mg/ml
heparin for 16 h before experiment. Mouse 3T3-L1 fibroblasts (American Type
Culture Collection, Middlesex, UK) were maintained in DMEM supplemented
with 10% calf serum and 1% PEST (Invitrogen). Confluent 3T3-L1 cells were
differentiated in DMEM, 10% FBS (PAA gold), 1% PEST, 1 mM Dexamethasone
(Sigma), 0.5 mM IBMX (Sigma) and 0.17 mM insulin (Novo Nordisk, Denmark).
Cells were serum starved in OptiMEM I (Invitrogen) containing 0.5% essentially
fatty acid free BSA (Sigma) 16 h before experiment. Cells were incubated with or
without 50 mg/ml antibodies for 1 h with or without 10 ng/ml FGF2
(MedImmune) for 10 min (PBS was used as control). Cultured cells were lysed in
lysis buffer (50 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 50 mM
sodiumfluoride, 5 mM pyrophosphate, 0.27 M sucrose, 1% (v/v) Triton-X 100
and 1 mM sodium orthovanadate) with a protease inhibitor cocktail and
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phosphoSTOP as above. Primary antibodies for Western blot analyses were from
Abcam [pPDK #52893], Sigma [a-Tubulin #T6074] or from Cell Signaling
Technology (Beverley, MA), pFGFR (Tyr653/654 #3471), pPLCc1 (Tyr783
#2821), pFRS2a (Tyr436 #3861), pAkt (Ser473 #4058L), pERK1/2 (Thr202/
Tyr204 # 4377), pStat3 (Tyr705 #9131S), pp70S6K1 (Thr389 #9205), pMEK
(#9154S), pJak2 (Tyr1007/1008 #3776S), pJNK (#4668P), and pp38 MAPK
(T180/Y182 #4511P). HRP-conjugated polyclonal goat anti-Rabbit P0448
(DAKO) was used as secondary antibody except for the anti a-Tubulin antibody
where an HRP conjugated goat anti-mouse P0447 (DAKO) was used. Enhanced
chemiluminescence reagents (Pierce) were used for detection.
Table 1. Primer and Probe sequences for quantitative RT-PCR.
Gene Forward (59-39) Reverse (59-39) Probe (59-39)
Agrp CGGAGGTGCTAGATCCACAGA AGGACTCGTGCAGCCTTACAC CGAGTCTCGTTCTCCGCGTCGC
Cart CTGCAATTCTTTCCTCTTGAAGTG GGGAATATGGGAACCGAAGGT SYBR
Ccr2 AGAAGTTCCGAAGGTATCTCTCCAT CCCTATAGAAAACTGGGCACTGTT TTTTTCAGAAAGCACATTGCTAAACGTCTCTGC
Ccr5 CTTCATGTTAGATTTGTACAGCTCTCCTA CATCCTGCAAGAGCCAGAGTCT CCAGAGGAGGTGAGACATCCGTTC
Cd11c CCACTGTCTGCCTTCATATTCATG CATGGTCTAGAGCCAGGTCAAAG CCAAGACCCAACTAGGTGACCTCCGAAGTA
Crh GGAGCCGCCCATCTCTCT CGGGCCATTTCCAAGACTT SYBR
Cx3cl1 CGCGTTCTTCCATTTGTGTACTC GCACATGATTTCGCATTTCG CTGCCGGGTCAGCACCTCGG
Cxcl12 CTGAAAATCCTCAACACTCCAAACT GCACACTTGTCTGTTGTTGTTCTTC TGCCCTTCAGATTGTTGCACGGC
Cxcl5 GCTGGCATTTCTGTTGCTGTT GCTCCGTTGCGGCTATGA CGCTGCCGCAGCATCTAGCTGAAG
Il-1b AATCTATACCTGTCCTGTGTAATGAAAGAC TGGGTATTGCTTGGGATCCA CACACCCACCCTGCAGCTGGAGA
Ifnc CAGCAACAGCAAGGCGAAA CTGGACCTGTGGGTTGTTGAC AGGATGCATTCATGAGTATTGCCAAGTTTGA
Lif CAACCTCATGAACCAGATCAA AAAGATGGGAAGTCTGTCATGTT AGAGAGCATTGGCGCTGCCA










Npy TACTCCGCTCTGCGACACTACA AATCAGTGTCTCAGGGCTGGAT SYBR
Orexin CTGCCGTCTCTACGAACTGTTG CGCTTTCCCAGAGTCAGGATA SYBR
Pgc-1a GTAGGCCCAGGTACGACAGC GCTCTTTGCGGTATTCATCCC ATGAAGCCTATGAGCACGAAAGGCTCAA
Pgc-1b CTCCAGGCAGGTTCAACCC GGGCCAGAAGTTCCCTTAGG CCCCCCAAAGCCTTCTGGACTGAGT
Pomc TGCTTCAGACCTCCATAGATGTGT GGATGCAAGCCAGCAGGTT SYBR
Ptgs1 TGGCCACATTTATGGAGATAAT GGACACCTGGTGGGTAGC CGTGGAACAGGCGTCCGTGT
Ptgs2 TCCAACCTCTCCTACTACACCA GGGTCAGGGATGAACTCTCT TGCTACGGGAGGAAGGGCCC
Socs3 CCGCGGGCACCTTTC TTGACGCTCAACGTGAAGAAGT CCGCGACAGCTCGGACCAGC
Tlr4 TCTGATCATGGCACTGTTCTTCTC TCTGATCCATGCATTGGTAGGT CCAGGAAGCTTGAATCCCTGCATAGAGGTAGT
Tnf-a ATGGCCCAGACCCTCACA TTGCTACGACGTGGGCTACA TCAGATCATCTTCTCAAAATTCGAGTGACAAGC
Ucp1 CTGGGCTTAACGGGTCCTG CTGGGCTAGGTAGTGCCAGTG AGCTCAAAGGTGAGCGTCCCTTCCTC
doi:10.1371/journal.pone.0112109.t001
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Immunohistochemical detection of c-Fos, human IgG and P-ERK in
the brain
Isoflurane anesthetized mice were transcardially perfused with heparinized saline,
followed by ice-cold 4% phosphate-buffered (pH 7.4) paraformaldehyde. Brains
were held at 220 C̊ in cryoprotectant (50% PBS, 30% ethylene glycol, 20%
glycerol), removed from the skull and cut into three blocks (forebrain, midbrain,
and hindbrain). After multiple washes with PBS, the blocks were soaked in a
sucrose solution (18% sucrose, 0.05% sodium azide in 1.0 M PBS) for
cryoprotection. Blocks were then frozen and cut into 30 mm coronal sections in a
cryostat microtome. Sections were separated into 5 series. For immediate
processing, sections were held in PBS at 4 C̊, and for long term storage, in a
cryoprotectant solution at 220 C̊. With appropriate washes in PBS between
incubations, free-floating sections were pretreated with 0.5% sodium borohydride
in PBS to minimize aldehyde cross-linking of the fixative. Sections were then
treated with a hydrogen peroxide solution (1.5% H2O2, 20% methanol, 0.25%
Triton X-100 in PBS) to minimize endogenous peroxidase activity. Sections were
finally placed in a blocking solution of 0.5% normal donkey serum in PBS
containing 0.5% Triton X-100 (PBST). The sections were incubated in primary
antibody (rabbit anti-c-Fos, 1:15 000; EMD Biosciences, La Jolla, CA, USA) in
primary diluent (PBST containing 0.1% gelatin and 0.05% sodium azide) for
24 hours at room temperature, or up to 48 hours at 4 C̊. They were then
incubated in secondary antibody (biotinylated donkey anti-rabbit, 1:500; Jackson
Immuno Research, West Grove, PA, USA) diluted in PBST for 2.5 hours at room
temperature. The sections were then treated with an avidin-biotin complex kit
(VECTASTAIN Elite ABC Kit, Vector Laboratories, Burlingame, CA, USA) for
1 hour at room temperature. Finally, the sections were visualized in a DAB
solution (0.5% 3,39-diaminobenzadine tetrahydrochloride, 1% cobalt chloride
and nickel chloride in stable hydrogen peroxide substrate buffer, Thermo
Scientific, Rockford, IL, USA) for 5 to 10 minutes at room temperature. For
double labeling, sections received a second incubation in the donkey serum
blocking solution. Sections were then incubated in primary antibody (rabbit anti-
human-IgG, 1:1000, AbD Serotec, Kidlington, UK; rabbit anti-pERK, 1:1000, Cell
Signaling Technology, Danvers, MA, USA) in primary diluent for 24 hours at
room temperature, or up to 48 hours at 4 C̊. They were then incubated in
secondary antibody (CY3 donkey anti-rabbit, 1:500, Jackson Immuno Research,
West Grove, PA, USA) for 2.5 hours at room temperature. Sections were washed
in PBS after every treatment step except between blocking with donkey serum and
incubation with primary antibody. All incubations were carried out with gentle
agitation from an orbital shaker. Sections were mounted onto Superfrost glass
slides using Prolong Gold Antifade Reagent with DAPI (Invitrogen, Grand Island,
NY, USA) as the mounting medium. Sections were viewed using a Zeiss Axioplan
fluorescence microscope (Carl Zeiss Microscopy, Thornwood, NY, USA). Counts
were performed visually.
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Figure 1. Characterization of anti-FGFR1c (R1c) mAb. (A) Octet association and dissociation kinetic profile for the interaction between R1c mAb and
varying concentrations of human FGFR1c. R1c mAb binding to human FGFR1c (R1c), FGFR1b (R1b), FGFR2c (R2c), FGFR2b (R2b), FGFR3c (R3c), or
FGFR4 (R4) in an ELISA. (B) R1c mAb inhibition of FGF1, 2, 4, 5, and 6 binding to NIH3T3 cells overexpressing human FGFR1c measured by Ca2+ release
in a FLIPR assay. (C) R1c mAb inhibition of FGF2, FGF19, FGF21, and FGF23 induced BaF3huFGFR1c cell proliferation. b-klotho was overexpressed in
the FGF19 and FGF21 assays and a-klotho was overexpressed in the FGF23 assay. n53 wells per treatment. Values are means ¡ SEM.
doi:10.1371/journal.pone.0112109.g001
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Statistics
The animals were randomized to experimental groups based on body weights
before treatment start. Differences between two groups were examined for
statistical significance using Mann-Whitney U-test. For multiple groups, Kruskal-
Wallis ANOVA was used followed by Mann-Whitney U-test. CLAMS P-values
Figure 2. FGFR1c mAb effects on FGFR and intracellular downstream signalling. Representative
Western blot analyses on FGFR1c (R1c) mAb (50 mg/ml), control mAb (50 mg/ml) and FGF2 (10 ng/ml)
treated (A) mouse embryonic hypothalamic N46 cells, (B) undifferentiated 3T3-L1 cells and (C) differentiated
3T3-L1 cells (D). White adipose tissue Western blot analyses after treatment of female diet-induced obese
(DIO) mice with a single injection of either R1c mAb or control mAb (10 mg/kg i.v.). The mice were fasted
during the treatment period.
doi:10.1371/journal.pone.0112109.g002
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were calculated using the MIXED procedure in SPSS. Values are presented as
means ¡ SEM. P,0.05 was considered significant.
Results
Identification and in vitro characterization of the anti-FGFR1c
antibody
A monoclonal antibody directed against human FGFR1c (R1c mAb) was
identified by scFv phage display selection. On conversion to the IgG form, the R1c
mAb bound human and mouse FGFR1c and did not bind to the other FGF
receptors FGFR1b, FGFR2b and c, FGFR3c, or FGFR4 (Fig. 1A, data for mouse
not shown). R1c mAb inhibited FGF1, FGF2, FGF4, FGF5 and FGF6 induced Ca2+
release in NIH3T3 cells overexpressing human FGFR1c (Fig. 1B). R1c mAb also
inhibited FGF2, FGF19 and FGF21 induced proliferation of BaF3huFGFR1c cells
transfected with b-Klotho (FGF19 and FGF21) but did not affect FGF23 induced
proliferation of BaF3huFGFR1c cells transfected with a-Klotho (Fig. 1C). Thus,
we have generated an FGFR1c-specific monoclonal antibody which blocks ligand-
induced FGFR1c activation.
R1c mAb was able to inhibit the FGF2 induced phosphorylation of FGFR and
major downstream signaling components including PLCc1, p70S6K1, FRS2a,
MEK, ERK1/2, JAK2, STAT3, AKT, JNK, and p38 (Fig. 2A). Furthermore, R1c
mAb inhibited FGF2-induced phosphorylation of FGFR, PLCc1, FRS2a and
ERK1/2 in both undifferentiated and differentiated 3T3-L1 cells. Interestingly, R1c
mAb also induced phosphorylation of ERK1/2 in both undifferentiated and
differentiated 3T3-L1 cells (Fig. 2B–C). In addition, R1c mAb treatment induced
acute phosphorylation of MEK and ERK1/2 in white adipose tissue (WAT)
(Fig. 1D), indicating that R1c mAb has dual antagonist/agonist properties.
R1c mAb reverses obesity and glucose intolerance via decreased
food intake
Dosing DIO mice with a single i.p. injection of R1c mAb resulted in a significant
suppression of food intake commencing 4–6 h post-dose (Fig. 3A). R1c mAb
treatment decreased the average number of feeding bouts and the amount of food
consumed during each feeding bout 24 h post-treatment while the duration of
each bout was not affected up to 36 h post-treatment (data not shown). Thus,
although R1c mAb treatment markedly decreased total food intake, it did not
disrupt normal meal patterns. Using i.v. injection, food intake inhibition
commenced 2–4 h post-dosing, whereas using s.c. delivery, the onset of food
intake inhibition was delayed for more than 12 h (data not shown).
A single injection of R1c mAb (T1/2 at 10 mg/kg s.c.58 d) in DIO mice reduced
food intake below vehicle and control mAb levels for 14 days resulting in transient
body weight loss (Fig. 3B). A single injection of R1c mAb also reduced body
weights in lean chow fed mice (R1c mAb to 91.5¡1.4% vs. control mAb
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99.8¡0.7% (means ¡ SEM) of initial start weight (,20 g) 2.5 d after the
injection, *P,0.01, Mann-Whitney U-test, n56 per group, mAb 10 mg/kg i.v.).
Repeated R1c mAb dosing lead to sustained body weight loss in both male and
female DIO mice reaching levels of age-matched lean mice (Fig. 3C) associated
with reduced body fat mass (Fig. 3D).
Figure 3. FGFR1c mAb effects on food intake, body weight and body composition. (A) 24 h cumulative
food intake and Bi-hourly food intake during the first 12 h following a single injection of either R1c mAb or
control mAb in female DIO mice (n54, 10 mg/kg i.p. indicated with an arrow). *P,0.05 vs. control mAb, Mann
Whitney U-test. (B) Body weight (n54), percent body weight change (n54) and food intake (n51, group
housed animals) following a single injection of either vehicle, R1c mAb or control mAb in female DIO mice
(10 mg/kg s.c. indicated with an arrow). (C) Body weight and body weight change following repeated
injections of either R1c mAb or control mAb in female or male DIO mice (n57–8, 10 mg/kg i.p. once weekly
indicated with arrows) compared with untreated lean mice on chow diet (n58–10). (D) Quantitative
assessment of body fat mass and body lean mass by dual-energy X-ray absorptiometry in female DIO mice
(n57, 10 mg/kg i.p. day 0, 7, 14 and 21). *P,0.05, **P,0.01, and ***P,0.001 R1c mAb fat mass vs. control
mAb fat mass and #P,0.05, and ##P,0.01 R1c mAb lean mass vs. control mAb lean mass at corresponding
treatment day, Mann Whitney U-test. Values are means ¡ SEM.
doi:10.1371/journal.pone.0112109.g003
FGFR1c MAb Ameliorates Obesity via Central Mechanisms
PLOS ONE | DOI:10.1371/journal.pone.0112109 November 26, 2014 13 / 26
R1c mAb treatment did not affect active time, latency to enter open
compartments nor the time spent in the closed or open compartments in a zero
maze assessment (data not shown). Furthermore, R1c mAb treated mice did not
display signs of impaired memory learning ability in a passive avoidance test or
Figure 4. FGFR1c mAb effects on glucose tolerance and pancreatic islet cell mass. (A) Oral glucose
tolerance test (OGTT) 15 d after repeated injections of either R1c mAb or control mAb in female or male DIO
mice (n57–8, three i.p. injections 10 mg/kg on day 0, 7 and 14). Glucose and insulin area under the curve
(AUC) were calculated. **P,0.01 and ***P,0.001 vs. respective control mAb, Mann Whitney U-test. (B)
Representative pancreatic islet staining of insulin (green), glucagon (red), and nucleuses (blue), and (C) b and
a cell quantification after repeated injections with either R1c mAb or control mAb in female DIO mice after 28 d
treatment (n57, 10 mg/kg i.p. day 0, 7, 14 and 21). N.S. 5 Non Significant. (D) Percent body weight change
after a single injection of R1c mAb in female DIO mice fed ad libitum (ad lib) or control mAb treated female
DIO mice fed ad lib or pair-fed (pf) twice daily to match the food intake in R1c mAb treated female DIO mice
fed ad lib (n56, 3 mg/kg s.c., indicated with an arrow). **P,0.01 R1c mAb ad lib vs. control mAb ad lib,
##P,0.01 control mAb pf vs. control mAb ad lib, and 1P,0.05 R1c mAb ad lib vs. control mAb pf, Mann
Whitney U-test. (E) Effects on 3 h fasting glucose levels before treatment start day 0 and after 4 d treatment.
**P,0.01 vs. Treatment day 0 within respective treatment group, Mann Whitney U-test. (F) Effects on 3 h
fasting insulin levels after 4 d treatment. *P,0.05, **P,0.01 vs. Control mAb fed ad lib, Mann Whitney U-test.
Values are means ¡ SEM.
doi:10.1371/journal.pone.0112109.g004
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any signs of depression in a forced swim test (data not shown), indicating that R1c
mAb did not induce general behavior changes in mice.
R1c mAb treatment improved oral glucose tolerance in both female and male
DIO mice (Fig. 4A) and pancreas histology revealed normal a- and b-cell
distribution and islet structure (Fig. 4B–C). R1c mAb treatment decreased the
WAT and liver weights and plasma ALT and leptin levels in DIO mice compared
with control mAb treatment while there was no effect on plasma levels of
triglycerides, NEFA or total adiponectin (Table 2). Interestingly, in a pair-feeding
experiment, pair-fed control mAb treated DIO mice lost the same amount of body
weight and reduced fasting glucose and insulin levels to similar extent as R1c mAb
treated DIO mice fed ad libitum (Fig. 4D–F). Thus, the R1c mAb induced
improvement in glucose control was most likely due to the reduction in food
intake and body weight loss.
There was no significant difference between R1c mAb and control mAb treated
female DIO mice on total energy expenditure, spontaneous locomotor activity
(Fig. 5A), or core body temperature (data not shown) while RER was decreased
following R1c mAb treatment (Fig. 5B), indicating a switch to more fatty acid
oxidative metabolism during the weight loss observed during the acute treatment
period (Fig. 5C). The same findings were observed in male DIO mice after acute
R1c mAb treatment and when examined on day 13–15 after treatment start, no
significant changes were observed on energy expenditure, RER or spontaneous
locomotor activity (data not shown). R1c mAb treatment only modestly increased
brown adipose tissue (BAT) peroxisome proliferator-activated receptor c
coactivator-1 (Pgc-1)a and uncoupling protein 1 (Ucp1) (compared to control
mAb treated mice fed ad libitum) and Pgc-1b (compared to pair-fed control mAb)
mRNA levels (Fig. 5D). R1c mAb also elevated WAT Pgc-1b mRNA levels but the
WAT Ucp1 mRNA levels were below detection limits. Collectively, these data
show that the R1c mAb mediated body weight loss is primarily driven via a
reduction in food intake and not enhanced energy expenditure.
Table 2. FGFR1c (R1c) mAb effects on organ weights and plasma biochemistry.
Liver WAT Triglycerides NEFA b-hydroxybutyrate ALT Leptin Adiponectin




1.13¡0.02 3.14¡0.13 0.28¡0.01 0.30¡0.01 360.1¡33.0 1.15¡0.13 28.0¡2.4 0.87¡0.05




1.71¡0.14 2.04¡0.15 0.50¡0.06 0.46¡0.02 299.1¡40.1 1.35¡0.15 22.1¡3.0 0.49¡0.03
R1c mAb 1.12¡0.04** 0.94¡0.08*** 0.47¡0.03 0.44¡0.01 297.7¡46.4 0.63¡0.04*** 3.7¡1.3 0.43¡0.02
Female or male DIO mice were treated with either R1c mAb or control mAb (n57–8, 10 mg/kg i.p. once weekly for 3 w, males or 4 w, females). *P,0.05,
**P,0.01, ***P,0.001 vs. control mAb, Mann Whitney U-test. Values are means ¡ SEM.
doi:10.1371/journal.pone.0112109.t002
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Role of hypothalamic neuronal circuits for the effects of R1c mAb
R1c mAb also decreased the body weight in leptin-deficient ob/ob mice, leptin
receptor-mutant db/db mice, melanocortin 4 receptor (Mc4r)-deficient mice and
melanin-concentrating hormone receptor 1 (Mchr1)-deficient mice (Fig. 6A). In
addition, R1c mAb did not affect hypothalamic mRNA expression levels of
cocaine- and amphetamine-regulated transcript (Cart), pro-opiomelanocortin
(Pomc), neuropeptide Y (Npy), corticotropin-releasing hormone (Crh), Mch, or
Orexin (Hcrtr) in DIO mice compared with control mAb treated DIO mice fed
Figure 5. FGFR1c mAb effects on energy expenditure and spontaneous locomotor activity. (A) Energy
expenditure, spontaneous locomotor activity and (B) respiratory exchange ratio measured with a CLAMS
open circuit indirect calorimetry system following a single injection with either R1c mAb or control mAb in
female DIO mice (n57, 10 mg/kg i.p. indicated with an arrow). ***P,0.001 vs. Control mAb, linear mixed
model, N.S. 5 Non Significant. (C) Body weight change during the treatment period (42 h). **P,0.01 vs.
control mAb, Mann Whitney U-test. (D) mRNA expression in brown adipose tissue (BAT) and ovarian white
adipose tissue (WAT) 4 d after a single injection of R1c mAb in female DIO mice fed ad libitum (ad lib) or
control mAb treated female DIO mice fed ad lib or pair-fed (pf) twice daily to match the food intake in R1c mAb
treated female DIO mice fed ad lib (n56, 3 mg/kg s.c.). *P,0.05 vs. control mAb ad lib group; #P,0.05 vs.
control mAb pf group, Mann Whitney U-test. Values are means ¡ SEM.
doi:10.1371/journal.pone.0112109.g005
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Figure 6. FGFR mAb effects in genetically obese mice and hypothalamic expression of neuropeptides and cytokines. (A) Change in body weight
one week after a single injection of R1c mAb or control mAb (n58 for ob/ob, n54 for others, 10 mg/kg s.c.) in mice lacking leptin (ob/ob), functional leptin
receptor (db/db), melanocortin 4 receptor (Mc4r-/-) or melanin-concentrating hormone receptor 1 (Mchr1-/-), compared to DIO mice. *P,0.05 and ***P,0.001
vs. control mAb, Mann Whitney U-test. (B) Neuropeptide mRNA expression and (C) Cytokine mRNA expression in hypothalamus, 4 d after a single injection
of R1c mAb in female DIO mice fed ad libitum (ad lib) or control mAb treated female DIO mice fed ad lib or pair-fed (pf) twice daily to match the food intake in
R1c mAb treated female DIO mice fed ad lib (n56, 3 mg/kg s.c.). *P,0.05, **P,0.01 vs. control mAb ad lib group; #P,0.05 vs. control mAb pf group, Mann
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either ad libitum or pair-fed to match the food intake of R1c mAb treated DIO
mice (Fig. 6B and data not shown). Hypothalamic mRNA expression of agouti-
related protein (Agrp), increased in both R1c mAb and pair-fed control mAb
treated DIO mice compared to control mAb treated DIO mice fed ad libitum
(Fig. 6B). These results indicate that R1c mAb might cause food intake inhibition
via other mechanisms than the classical hypothalamic neuronal circuits known to
be of importance for regulation of food intake.
Effects of R1c mAb on hypothalamic cytokine levels
In conditions like cachexia, cytokines are strongly implicated in the mechanism
controlling the cessation of food intake, reviewed in [11]. Interestingly, R1c mAb
markedly elevated Monocyte chemoattractant protein (Mcp)1, Mcp2 (Ccl7), Mcp3
(Ccl8) and C-X-C motif chemokine 5 (Cxcl5) mRNA levels in the hypothalamus
4 d post-dosing while the mRNA expression levels of tumor necrosis factor a
(Tnfa), interleukin (Il)-1b, Il-6, C-C chemokine receptor (Ccr)2, Ccr5, Cd11c,
stromal-cell derived factor 1 (Cxcl12), Cx3cl1, interferon c (Ifnc), leukemia
inhibitory factor (Lif), prostaglandin-endoperoxide synthase (Ptgs, cyclooxygen-
ase)1, Ptgs2, suppressor of cytokine signaling 3 (Socs3), or toll-like receptor 4
(Tlr4) were unaltered compared to pair-fed control mAb treated DIO mice (Fig. 6
and data not shown). Thus, R1c mAb treatment induced expression of a specific
subset of chemokines in the hypothalamus.
Detailed studies showed that Mcp1 and Mcp3 mRNA levels were elevated in the
hypothalamus already 3 h after R1c mAb i.v. injection, coinciding with initiation
of food intake suppression. The Mcp1 and Mcp3 expression levels were highly
elevated 12 h post-injection and remained increased 5 d post-injection while the
related cytokine Mcp2 was not increased by R1c mAb at any time point (Fig. 6D).
Furthermore, Tnfa mRNA levels were elevated in the hypothalamus 12 h and 5 d
post-injection, whereas Il-1b was only significantly increased 12 h after R1c mAb
injection compared with fasted control mAb treated DIO mice. Importantly,
fasting in itself did not affect hypothalamic mRNA expression levels of Mcp1,
Mcp2, Mcp3, or Il-1b (Fig. 6D). Liver Mcp1 mRNA expression and plasma MCP1
levels were not elevated by R1c mAb treatment at any time point (data not
shown). Thus, R1c mAb induced a rapid and marked elevation in hypothalamic
Mcp1 and Mcp3 cytokine expression in a time frame that coincides with initiation
of food intake suppression.
Whitney U-test. (D) Cytokine mRNA expression in hypothalamus 3 h, 12 h and 5 d after a single injection of R1c mAb in female DIO mice fed ad lib
compared to control mAb treated mice fed ad lib or fasted for the duration after the treatment (n56, 10 mg/kg i.v.). *P,0.05 and **P,0.01 vs. control mAb ad
lib group; #P,0.05 and ##P,0.01 vs. control mAb fasted group, Mann Whitney U-test. Values are means ¡ SEM.
doi:10.1371/journal.pone.0112109.g006
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Figure 7. R1c mAb effects on c-Fos activation, human IgG accumulation and phosphorylation of ERK1/2 and p70S6K1 in the brain. (A)
Representative photomicrographs and (B) Quantification of R1c mAb induced neuronal activity as measured by c-Fos labelling 3 h after a single injection of
R1c mAb or control mAb in female DIO mice (n53–5, 10 mg/kg i.v., all mice fasted during the 3 h treatment period). *P,0.05, **P,0.01 vs. control mAb,
Mann Whitney U-test. Values are means ¡ SEM. (C) Accumulation of R1 mAb as shown by representative confocal microscope images detecting human
IgG 7 h after a single injection of R1c mAb in female DIO mice (10 mg/kg i.p.). (D) Western blot analyses of phosphorylation of ERK1/2 and p70S6K1 in the
hypothalamus 3 h and 12 h post-injection with R1c mAb in female DIO mice fed ad libitum (al) compared to control mAb treated mice fed al or fasted for the
duration after the injection. All mAbs were delivered at 10 mg/kg, i.v. and a-Tubulin is given as protein loading control. (E) Representative confocal
microscope images showing phosphorylated ERK (p-ERK) 7 h after a single injection of R1c mAb or control mAb in female DIO mice (10 mg/kg i.p., all mice
fasted during the 7 h treatment period). AP, area postrema; ARC, arcuate nucleus; ME, median eminence; NTS, nucleus tractus solitaries; PVH,
paraventricular hypothalamic nucleus; SFO, subfornical organ.
doi:10.1371/journal.pone.0112109.g007
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R1c mAb accumulation and activation of neurons and kinases in
the brain
To further explore which specific neuronal circuits and areas within the brain that
were affected by R1c mAb treatment, we first measured the expression of the
immediate early gene c-Fos, a reliable marker of neuronal activity. Interestingly, in
the area postrema and subfornical organ, there was a strong R1c mAb induced
neuronal c-Fos activation 3 h (Fig. 7A–B) and 12 h after an i.v. injection and 7 h
after an i.p. injection (data now shown). In contrast, the c-Fos signal in the
paraventricular nucleus of the hypothalamus was similar in both R1c and control
mAb treated mice (Fig. 7B). We could further confirm accumulation of human
IgG in the median eminence with a distinct labeling of tanycytes at the base of the
3rd ventricle and adjacent arcuate nucleus, as well as in the subfornical organ and
area postrema (Fig. 7C).
We hypothesized that if the dramatic increase in hypothalamic expression of
certain cytokines upon R1c mAb treatment was physiologically important, we
could expect to also see hypothalamic activation of ERK1/2 and p70S6K1
signaling pathways shown to be important for regulation of food intake [12–15].
R1c mAb increased hypothalamic phosphorylation of ERK1/2 and p70S6K1 12 h
post-injection, with a trend also 3 h post-injection (Fig. 7D). The increased
phosphorylation of ERK1/2 and p70S6K1 was not apparent 30 min post-injection
when food intake was not affected (data not shown). Thus, activation of protein
kinases ERK1/2 and p70S6K1 was associated with the initial time-course of food
intake suppression caused by R1c mAb treatment. In addition, using double-
labeling immunohistochemistry for p-ERK1/2 and c-Fos, R1c mAb treatment was
found to increase the phosphorylation of ERK1/2 in each of the three
circumventricular organs, particularly in the area postrema and subfornical organ
Figure 8. FGFR1c FAb fragment effects on FGFR1 down-stream signalling and body weight. (A) Representative Western blot analyses on FGFR1c
(R1c) Fab, control FAb, R1c mAb, control mAb (50 mg/ml) and FGF2 (10 ng/ml) treated undifferentiated 3T3-L1 cells. (B) Body weight following repeated
injection of either R1c FAb or control FAb fragments in female DIO mice (160 mg/kg/day, sc, BID, n54). *P,0.05, R1c FAb vs. control FAb at corresponding
treatment day, Mann Whitney U-test. Values are means ¡ SEM.
doi:10.1371/journal.pone.0112109.g008
FGFR1c MAb Ameliorates Obesity via Central Mechanisms
PLOS ONE | DOI:10.1371/journal.pone.0112109 November 26, 2014 20 / 26
compared to control mAb treated mice (Fig. 7E). Immunoreactivity seemed to be
mainly concentrated in dendritic/axonal processes rather than in neuronal
cytoplasm. Thus, increased phosphorylation of ERK1/2 implicates the ERK1/2
MAP kinase pathway within neurons of the circumventricular organs and in the
mediobasal hypothalamus in the food intake suppressing effect of R1c mAb
treatment.
R1c mAb agonism could be due to induced FGFR1c homodimerization leading
to ERK1/2 phosphorylation similar to endogenous agonists [16]. In an attempt to
see if FGFR1c antagonism only could cause weight-loss, a FAb fragment of the R1c
mAb was generated. In contrast to R1c mAb, R1c FAb did not induce
phosphorylation of ERK1/2 in 3T3-L1 cells but still antagonized FGF2 induced
ERK1/2 phosphorylation (Fig. 8A). In addition, R1c FAb still caused body weight
loss in DIO mice (Fig. 8B), showing that FGFR1c antagonism alone can cause
body weight loss.
Discussion
Previously described FGFR1c monoclonal antibodies affecting body weight in
animals have been claimed to be either purely antagonistic (IMC-A1) [4] or
agonistic [5]. Here we describe that an anti-FGFR1c monoclonal antibody can
possess both antagonistic and agonistic properties. R1c mAb was found to
selectively bind FGFR1c and to prevent binding of FGF1, FGF2, FGF4, FGF5, and
FGF6 to FGFR1c and to inhibit FGF2, FGF19, and FGF21 induced proliferation.
R1c mAb also antagonized FGF2 induced phosphorylation of FGFR and multiple
downstream signaling molecules in both neuronal N46 cells and 3T3-L1 cells.
Unexpectedly, R1c mAb also increased phosphorylation of ERK1/2 in both
undifferentiated and differentiated 3T3-L1 cells and in WAT after in vivo
treatment similar to the agonistic FGFR1 mAb described by Wu et al [5].
Recently, another ‘‘FGF21 mimetic’’ mAb targeting b-Klotho was found to
decrease body weight and improve glucose homeostasis in cynomolgus monkeys
[17]. At present, it is a bit unclear how R1c mAb can have dual antagonistic/
agonist actions but it does not seem to be related to absence or presence of b-
Klotho since b-Klotho was present in differentiated 3T3-L1 cells but not in
undifferentiated 3T3-L1 cells (data not shown). However, R1c FAb did not induce
ERK1/2 phosphorylation in 3T3-L1 cells, indicating that R1c mAb agonistic
action is due to induced FGFR1c homodimerization.
R1c mAb treatment modestly increased Pgc-1a, Pgc-1b and Ucp1 mRNA levels
in BAT but did not affect total energy expenditure in contrast to the agonistic
FGFR1 mAb described by Wu et al [5]. R1c mAb had however marked effects on
food intake and FGFR1 is expressed in many areas in the brain including areas
where R1c mAb accumulated such as the circumventricular organs, and in the
hypothalamus [18] and Fgfr1c has been shown to be the dominant isoform of
Fgfr1 in the hypothalamus [4]. R1c mAb treatment caused potent body weight
loss in DIO mice and the weight loss could be accounted for entirely by decreased
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food intake in a pair-feeding experiment. We further showed that R1c mAb also
caused marked body weight loss in ob/ob and db/db mice and in mice lacking the
Mc4r or Mchr1. In addition, R1c mAb did not affect hypothalamic expression
levels of Cart, Npy, Crh, Mch, Hcrtr/Orexin, or Agrp indicating that R1c mAb
could cause food intake inhibition via other mechanisms than through classical
hypothalamic neuronal circuits known to be of importance for regulation of food
intake [19].
Although we cannot exclude that circulating immune cells could play a role in
the R1c mAb mediated increase in hypothalamic expression levels of Mcp1, Mcp3,
Tnfa, and Il-1b, circulating levels of MCP1 and liver expression of Mcp1 were
unaffected, indicating a centrally mediated effect. CNS inflammation has
paradoxically been found to promote both positive and negative energy balance
[20]. HFD feeding promoted low grade hypothalamic inflammation in
experimental animals [21–26] while pharmacological or genetic inhibition of JNK
[21], IKKb/NF-kB [24,25], toll-like receptor 4 (TLR4) [23], or myeloid
differentiation factor 88 (MyD88) [22] decreased food intake leading to body
weight loss. Furthermore, short-term HFD feeding has been found to cause
hypothalamic reactive gliosis and neuronal injury in mice and hypothalamic
gliosis was also observed in obese humans [26]. On the other hand, conditions
associated with cachexia such as certain types of cancer, anorexia, fever,
anhedonia or exposure to bacterial endotoxins have also been associated with
increased levels of pro-inflammatory cytokines [11]. Lipopolysaccharide (LPS) -
or muramyl dipeptide-induced anorexia increased hypothalamic gene expression
of several cytokines [27] and central administration of MCP1, RANTES, IL-8, or
IL-1b has been shown to decrease food intake [28,29]. Both MCP1 and its
receptor CCR2 are expressed in astrocytes and neurons in the hypothalamus and
peripheral LPS administration was found to increase MCP1 binding in the
hypothalamus [30,31]. R1c mAb treatment did not affect core body temperature,
energy expenditure, spontaneous locomotor activity, muscle wasting, general
behavior or systemic MCP1 levels arguing against general inflammation-induced
cachexia as a mechanism for R1c mAb mediated inhibition of food intake and
body weight loss. Rather, the R1c mAb mediated marked induction of Mcp1 and
Mcp3 in the hypothalamus coinciding with the initiation of food intake
suppression could have direct effects on food intake inhibition. Interestingly,
Shirazi et al recently showed that glucagon-like peptide 1 (GLP-1, exendin-4)
mediated suppression of food intake and body weight was mediated by central
elevation of IL-6 and IL-1 [32], indicating that specific hypothalamic cytokines
could play a broader role in controlling food intake and body weight in response
to different pharmacotherapies than previously appreciated.
FGF1 and FGF2 have been implicated in the central regulation of food intake.
FGF1 levels were markedly increased in the cerebrospinal fluid following a meal or
i.p. injection of glucose and i.c.v. administration of FGF1 or FGF2 decreased food
intake in rats [33–35]. Administration of polyclonal anti-FGFR1 antibodies into
the bilateral lateral hypothalamic area increased food intake in rats [36],
indicating that the R1c mAb mediated decrease in food intake could at least partly
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be due to an FGFR1c agonistic action. Alternatively, the effect of R1c mAb on
food intake inhibition may be due to an FGFR1c antagonistic action as also
demonstrated using an antagonistic R1c FAb fragment. FGF1 and FGF2 are
abundant in the brain [18] and additional administration via i.c.v. injections of
FGF1 or FGF2 [33–35] may result in high ligand concentrations in the brain.
Excessive ligand concentrations may act in an antagonistic mode and other FGFRs
than FGFR1c may be important for the FGF signalling [37].
Clearly, effects of R1c mAb on the area postrema could be responsible for its
food intake and body weight-reducing effects, as this circumventricular area in the
caudal brainstem is intimately related to both ascending and descending
medullary structures involved in the control of food intake and energy balance
regulation, such as the nucleus of the solitary tract and the hypothalamus. The
strong activation of subfornical organ neurons was unexpected, as the role of this
circumventricular structure in food intake and energy balance regulation is less
well known. However, more recently a case has been made for such a role on the
basis of strong effects of relevant peptides such as leptin and orexin on neurons in
the subfornical organ [38–40]. It would be certainly worthwhile to pursue the role
of this area in the weight-reducing effects of the R1c mAb in addition to the
activation of tanycytes lining the ventral portions of the 3rd ventricle with
communication to the basomedial hypothalamus. Interestingly in this respect,
FGF2 was recently found to enhance proliferation of hypothalamic 3rd ventricle a-
tanycytes in vivo [41]. Additionally, Balland et al recently showed that re-
establishing ERK signalling in median eminence tanycytes (which is decreased in
DIO), restored both leptin transport to the hypothalamus and leptin sensitivity
[42]. It would thus be interesting for future studies to see if R1c mAb treatment
could affect leptin transport to the hypothalamus and leptin sensitivity in the
obese state.
R1c mAb treatment activated the FGFR1c downstream signalling proteins
ERK1/2 and p70S6K1 via phosphorylation in the hypothalamus associated with
the initial time-course of hypothalamic cytokine induction and suppression of
food intake and we could also detect phosphorylation of ERK1/2 in the
circumventricular organs. Leptin has also been found to activate ERK in the
hypothalamus and pharmacological blockade of ERK reversed the anorectic and
weight-reducing effects of leptin [14]. Similarly, amylin and cholecystokinin
(CCK) have been found to activate ERK in area postrema and nucleus tractus
solitarius, respectively and ERK inhibition attenuated the ability of amylin and
CCK to reduce food intake [13,15]. Overexpression of constitutively active
p70S6K1 in mediobasal hypothalamus has been shown to decrease food intake
protecting against HFD-induced obesity, fat deposition and insulin resistance
[12]. Thus, R1c mAb mediated suppression of food intake could be due to
activation of ERK1/2 and p70S6K1 in the hypothalamus.
R1c treatment markedly improved glucose tolerance in DIO mice. This was
most likely due to the decrease in food intake and body weight loss since pair-fed
control mAb treated DIO mice displayed similar improvements in fasting plasma
glucose and insulin levels as R1c mAb treated DIO mice. Furthermore, R1c mAb
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treatment did not influence pancreatic b and a cell mass or islets morphology.
Pancreatic overexpression of dominant-negative FGFR1c using the Ipf1/Pdx1
promoter has previously been shown to decrease the number of b-cells, change
islets morphology, and to cause diabetes in mice [43]. Marked overexpression of
dominant-negative FGFR1c already in the developing pancreas may have caused
developmental pancreas derangements as compared to treatment of DIO mice
with R1c mAb.
In summary, we have generated a novel human monoclonal antibody directed
against FGFR1c, R1c mAb, having dual antagonistic/agonistic properties.
Treatment of DIO mice with R1c mAb ameliorated obesity and glucose
intolerance due to decreased food intake and body weight loss. The decreased
food intake was associated with increased hypothalamic Mcp1 and Mcp3
expression and phosphorylation of ERK1/2 and p70S6K1.
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